AMPH - CIK 0001297184
Amphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $719.89M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $719.89M | -1.7% |
| FY 2024 | $731.97M | +13.6% |
| FY 2023 | $644.39M | +29.1% |
| FY 2022 | $498.99M | +14.0% |
| FY 2021 | $437.77M | +25.1% |
| FY 2020 | $349.85M | +8.5% |
| FY 2019 | $322.36M | +9.4% |
| FY 2018 | $294.67M | +22.7% |
| FY 2017 |
Amphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $719.89M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2012 and fiscal 2025, Amphastar Pharmaceuticals, Inc.'s revenue grew from $204.32M to $719.89M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $240.18M |
| -5.9% |
| FY 2016 | $255.16M | +1.4% |
| FY 2015 | $251.52M | +19.5% |
| FY 2014 | $210.46M | -8.4% |
| FY 2013 | $229.68M | +12.4% |
| FY 2012 | $204.32M | - |